Ra Pharma (RARX) PT Raised to $49 at Raymond James After Successful Phase 2 Trial
Tweet Send to a Friend
Raymond James analyst Steven Seedhouse raised the price target on Ra Pharma (NASDAQ: RARX) to $49.00 (from $44.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
